Seres Therapeutics presented preclinical data at Digestive Disease Week 2026 supporting SER-603, a next-generation live biotherapeutic designed to treat inflammatory bowel disease (IBD). SER-603 targets microbial functions linked to mucosal healing and inflammation, aiming to improve gut barrier integrity and reduce inflammatory bacteria. The therapy complements existing treatments and is being advanced through IND-enabling activities with potential for both monotherapy and combination use. This development highlights Seres' innovative approach to microbiome-based therapies for IBD, with ongoing efforts to stratify patients using microbiome biomarkers for better treatment outcomes.
The Dow Jones reached a record high of 50,579.70 while the S&P 500 logged its eighth consecutive weekly gain despite consumer sentiment hitting a record low. Brent crude oil remains above $103 per barrel due to supply risks around the Strait of Hormu...
BioLineRx, a clinical-stage biopharmaceutical company, will release its Q1 2026 financial results on May 27, 2026. Analysts expect an earnings loss of $1.04 per share and revenue of $343,000, reflecting ongoing development costs typical for its growt...
Google Cloud Security used the Instruqt platform to train over 150 professionals on Agentic AI during the Google Next 2026 conference. Each participant worked in a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, ...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 practitioners on Agentic AI. Each participant received a dedicated Vertex AI environment to build their own AI agents hands-on, moving beyond slide-based demos. T...
At Google Next 2026, Google Cloud Security used the Instruqt platform to train over 150 professionals in agentic AI capabilities. Each participant received a dedicated Google Cloud Vertex AI environment to build and explore AI agents hands-on, moving...
